EXEL vs. NTRA: Exelixis vs. Natera Stock Comparison

Company Profile

Exelixis (EXEL) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while Exelixis (EXEL) is defensive at 0.41 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Exelixis (EXEL) reports 44.32%, ranking against industry peers normally.

Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Exelixis (EXEL) reports 35.45%, ranking against industry peers normally.

Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Exelixis (EXEL) reports 40.75%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Exelixis (EXEL) at 6.98% and Natera (NTRA) at 35.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Exelixis (EXEL) at 3.21 and Natera (NTRA) at 2.81 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Exelixis (EXEL) at 0.09 and Natera (NTRA) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Exelixis (EXEL) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Exelixis (EXEL) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Exelixis (EXEL) trades at 20.83 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.

On P/S ratio, both Exelixis (EXEL) at 6.80 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: Exelixis (EXEL) at 9.28 sits in the upper P/B ratio quartile, and Natera (NTRA) at 23.99 prices even higher, above its industry range.

Valuation Metrics